Chungyong Han
Overview
Explore the profile of Chungyong Han including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Lee H, Go E, Lee S, Han C, Choi Y
J Control Release
. 2024 Oct;
376:108-122.
PMID: 39384151
Immune checkpoint inhibitors (ICIs) are innovative immunotherapeutic agents for cancer. However, their low therapeutic efficacy in patients with large or rapidly growing tumors, along with their high cost, represents a...
2.
Cho E, Han S, Eom H, Lee S, Han C, Singh R, et al.
Int J Mol Sci
. 2023 Sep;
24(18).
PMID: 37761976
The interaction between regulatory T (Treg) cells and self-reactive T cells is a crucial mechanism for maintaining immune tolerance. In this study, we investigated the cross-activation of Treg cells by...
3.
Cho E, Singh R, Han C, Kim S, Kim K, Park B, et al.
Cell Mol Immunol
. 2023 Jun;
20(9):1077-1080.
PMID: 37365325
No abstract available.
4.
Kim S, Go E, Shin D, Choi B, Han C
Cells
. 2022 Dec;
11(23).
PMID: 36497152
In adoptive T cell therapy (ACT), the transfer of tumor-specific T cells is paralleled by the conditioning regimen to increase therapeutic efficacy. Pre-conditioning depletes immune-suppressive cells and post-conditioning increases homeostatic...
5.
Shin D, Kim S, Choi M, Bae Y, Han C, Choi B, et al.
Oncogene
. 2021 Nov;
41(2):280-292.
PMID: 34743207
We previously found the SLC3A2-NRG1 (S-N) fusion gene in a lung adenocarcinoma specimen without known driver mutations and validated this in 59 invasive mucinous adenocarcinoma (IMA) samples. Interestingly, KRAS mutation...
6.
Kim S, Cho E, Kim Y, Han C, Choi B, Kwon B
Nat Commun
. 2021 Sep;
12(1):5314.
PMID: 34493727
Adoptive T cell therapy (ACT) requires lymphodepletion preconditioning to eliminate immune-suppressive elements and enable efficient engraftment of adoptively transferred tumor-reactive T cells. As anti-CD4 monoclonal antibody depletes CD4 immune-suppressive cells,...
7.
Yu E, Cho E, Singh R, Kim S, Han C, Han S, et al.
Cells
. 2021 Aug;
10(8).
PMID: 34440787
Adoptive cell therapy (ACT) using tumor-reactive T cells is a promising form of immunotherapy to specifically target cancer. However, the survival and functional maintenance of adoptively transferred T cells remains...
8.
Kim S, Singh R, Han C, Cho E, Kim Y, Lee D, et al.
Cell Mol Immunol
. 2020 Sep;
18(8):1956-1968.
PMID: 32868911
The antitumor capabilities of agonistic anti-4-1BB mAbs have made them an attractive target for tumor immunotherapy. However, the adverse side effects associated with agonist antibodies have hindered their clinical development....
9.
Shin D, Jo J, Kim S, Choi M, Han C, Choi B, et al.
Cancers (Basel)
. 2020 Aug;
12(9).
PMID: 32847073
Hypoxia-inducible factors (HIFs) induced by reduced O availability activate the transcription of target genes encoding proteins that play important roles in communication between cancer and stromal cells. Cancer cells were...
10.
Han C, Choi B, Kim S, Sim S, Han S, Park B, et al.
Mol Ther Oncolytics
. 2020 May;
17:293-305.
PMID: 32368617
Antibody applications in cancer immunotherapy involve diverse strategies, some of which redirect T cell-mediated immunity via engineered antibodies. Affinity is a trait that is crucial for these strategies, as optimal...